"Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone."
biospace.com/article/releas...
NPfisherman is the science coming???? 😀
It's nice to see all these new treatments coming on line.
Good. Wonder if the average person that needs it will be able to afford it.
Is this classified as an immunotherapy drug. Just like all these different treatments they work for some and not for others.
Entering Clinical Trials
Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, AdvancingGood news for mCRPC (hopefully), phase 2
PSMAddition Phase 1/2 Results?
New Drug BAY1841788 (ODM-201) has been successful for CRPC patients, Clinical trial Phase III completed.
